Viewing Study NCT00003358


Ignite Creation Date: 2025-12-25 @ 12:01 AM
Ignite Modification Date: 2026-01-24 @ 4:27 PM
Study NCT ID: NCT00003358
Status: COMPLETED
Last Update Posted: 2013-01-16
First Post: 1999-11-01
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Fallopian Tube Cancer View
None Ovarian Cancer View
None Primary Peritoneal Cavity Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None stage I ovarian epithelial cancer View
None stage II ovarian epithelial cancer View
None stage III ovarian epithelial cancer View
None stage IV ovarian epithelial cancer View
None recurrent ovarian epithelial cancer View
None fallopian tube cancer View
None primary peritoneal cavity cancer View